當(dāng)?shù)貢r(shí)間2023年6月12日，三優(yōu)生物醫(yī)藥（上海）有限公司正式宣布，“三優(yōu)超萬億共同輕鏈抗體發(fā)現(xiàn)平臺”隆重上線。

共同輕鏈抗體發(fā)現(xiàn)平臺是三優(yōu)生物九大萬億級抗體發(fā)現(xiàn)平臺之一，庫容高達(dá)1.12E+12 CFU。針對單一靶點(diǎn)，該平臺可篩選出數(shù)百個(gè)分子序列差異大的先導(dǎo)分子，進(jìn)一步組裝后，可獲得成藥性良好的雙抗，這為獲得構(gòu)型與經(jīng)典天然單克隆抗體相似的構(gòu)型，卻有雙特異性的雙抗提供了基礎(chǔ)。

雙抗藥物的開發(fā)正處于抗體研發(fā)浪潮的前端，與單克隆抗體相比，雙抗增加了一個(gè)特異性抗原結(jié)合位點(diǎn)，為抗體帶來了更強(qiáng)的特異性和更好的靶向性。截至2023年3月，全球有436項(xiàng)雙抗藥物處于臨床試驗(yàn)階段，并已有10款雙抗藥物獲批上市，銷售額超過50億美元。

三優(yōu)生物共同輕鏈抗體發(fā)現(xiàn)平臺的分子庫的建立過程非常嚴(yán)謹(jǐn)，經(jīng)由1800+輕鏈序列比對篩選，25個(gè)預(yù)建庫的驗(yàn)證，12條輕鏈的抗體表征分析，最終優(yōu)選2條輕鏈而建成。該平臺篩選出的雙抗分子成藥性好，且重鏈遵循自然，多樣性高。該平臺，搭載的Knob-into-hole技術(shù)保障雙抗產(chǎn)生過程中的正確配對，消除了雙抗產(chǎn)生的錯(cuò)配難題，適用于雙抗開發(fā)、雙靶或雙表位ADC、治療或檢測抗體等應(yīng)用場景。

三優(yōu)生物共同輕鏈抗體發(fā)現(xiàn)平臺以客戶需求為中心，配備了庫篩選和庫嫁接兩種類型的服務(wù)，不僅適用于單個(gè)項(xiàng)目的研發(fā)，還可以為客戶獨(dú)家定制子庫平臺嫁接服務(wù)。

相信，三優(yōu)生物共同輕鏈抗體發(fā)現(xiàn)平臺的上線后，將為客戶提供重磅助力，攻克雙抗藥物的研發(fā)難點(diǎn)，降低雙抗藥物可開發(fā)性的挑戰(zhàn)，極大加速雙特異性抗體的研發(fā)進(jìn)程！

關(guān)于三優(yōu)生物

三優(yōu)生物成立于2015年，是一家國際領(lǐng)先的專注于創(chuàng)新生物藥研發(fā)和服務(wù)的生物高科技企業(yè)。公司致力于打通藥物研究與開發(fā)“端對端”完整的供應(yīng)鏈，構(gòu)建“差異化CRO、整合型CDO、協(xié)同型CPO、特色CRS”于一體的4C業(yè)務(wù)體系，實(shí)現(xiàn)“讓天下沒有難做的創(chuàng)新生物藥”的使命。

三優(yōu)生物建立了20000余平方米、設(shè)施設(shè)備先進(jìn)齊全的創(chuàng)新生物藥一體化研發(fā)實(shí)驗(yàn)室。公司打造了居于行業(yè)領(lǐng)軍水平的“超萬億、一體化、智能化”三大創(chuàng)新藥研發(fā)技術(shù)平臺，及以超萬億噬菌體展示抗體庫為代表的，涵蓋原材料制備、分子發(fā)現(xiàn)、分子優(yōu)化、體內(nèi)外藥效、生產(chǎn)用細(xì)胞株構(gòu)建、上下游工藝開發(fā)、臨床前研發(fā)及產(chǎn)業(yè)化開發(fā)等50多個(gè)核心創(chuàng)新技術(shù)子平臺。

公司持續(xù)推出“創(chuàng)新、卓越、可靠”（三優(yōu)）的新技術(shù)、新產(chǎn)品、新服務(wù)和新場景，并和全球1000多家制藥公司、藥物研發(fā)機(jī)構(gòu)、診斷試劑產(chǎn)品公司建立了友好的業(yè)務(wù)合作關(guān)系。

Sanyou Milestones | Super Trillion Common Light Chain Antibody Discovery Platform Launched

On June 12th, 2023 local time, Sanyou Biopharmaceuticals Co., Ltd. officially announced the launch of "Sanyou Super Trillion Common Light Chain Antibody Discovery Platform" (the "platform").

As one of the nine trillion antibody discovery platforms of Sanyou, the platform features a library capacity of up to 1.12E+12 CFU. For a single target, the platform can generate hundreds of lead antibodies with diverse sequences, which can be further designed into bispecific antibodies with good drug developability, providing a feasible solution for obtaining bispecific antibodies with structures similar to the natural monoclonal antibodies.

Bispecific antibodies are at the forefront of antibody R&D field. Compared with monoclonal antibodies, bispecific antibodies possess one additional antigen binding arm, which brings stronger specificity and better targeting. As of March of 2023, 436 bispecific antibody drug candidates have advanced to clinical trials worldwide, and 10 bispecific antibody drugs had been approved for marketing, with sales of more than 5 billion USD.

The antibody library of the platform was established in a rigorous way. To be specific, 2 common light chains were selected through alignment and screening of 1800+ light chain sequences, validation of 25 proof-of-concept libraries, and antibody characterization and analysis of 12 light chains. The bispecific antibodies generated by this platform exhibit good drug developability, and the heavy chains possess natural antibody properties and high diversity. The platform employs the Knob-into-hole technology to ensure the correct pairing in the process of bispecific antibody formation and eliminate the mismatch. These common light chain antibodies are suitable for multiple application scenarios, such as bispecific antibody development, dual-targeting or bi-paratopic ADC, and therapeutic or detection antibodies.

Following the customer-oriented concept, the platform provides two types of services, i.e., library screening and library integration, making it not only suitable for the R&D service of individual projects, but also for customers’ integration into their own platforms with the exclusively customized common light chain libraries.

It is believed that the launch of the platform will provide customers with great assistance in overcoming the difficulties in the R&D of bispecific antibody drugs, reducing the challenges in the development of bispecific antibody drugs, and greatly accelerating the R&D of bispecific antibodies.

About Sanyou Bio

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biological drugs. Sanyou is committed to bridge drug R&D and all-life-cycle manufacture supply chain, and has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS”, to accomplish the mission “to make it easy to discover innovative biological drugs anywhere”.

Sanyou has established an integrated innovative biological drug R&D laboratory of twenty thousand square meters with advanced facilities, and has built three industry-leading innovative technology platforms featured by “super-trillion, integration, and intelligence" , which are comprised of more than 50 sub-platforms with the core innovative super-trillion phage display platform, and supported by platforms of material preparation, antibody discovery, molecule optimization, in vitro and in vivo efficacy, production cell line construction, upstream and downstream process development, preclinical R&D, industrialization development, etc.

Sanyou’s proprietary platform and technology are in continuous optimisation, we launch from time to time upgrades and new version of services and technologies based on principles of innovation, outstanding and reliability. The company has established friendly business collaboration with more than 1000 pharmaceutical companies, drug R&D institutions and diagnostics companies worldwide.

關(guān)鍵詞：